Rifampicin resistance profile of Mycobacterium tuberculosis isolated from human patients

Proceedings of the Pakistan Academy of Sciences

Volumn 46, Issue 3, 2009, Pages 131-136

  Nazir, Taha ^a   Hameed, Abdul ^b   Qureshi, Javed Anver ^c   Ahmad, Bashir ^d   Abraham, Suraj ^e  

^a UNIVERSITY OF SARGODHA   (Pakistan)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

^c NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

^d UNIVERSITY OF THE PUNJAB   (Pakistan)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

M. tuberculosis; Multidrug resistance; Rifampicin susceptibility

Indexed keywords

EID: 70450189213     PISSN: 03772969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dolan, P.J., Raviglione, M.C. and Kochi, A. 1993. Estimates of future global tuberculosis morbidity and mortality. MMWR 42:961-963.
2. WHO. 2004. Surveillance of Drug-Resistant Tuberculosis in South-East Asia. Report of an Intercountry Training Course, Bangalore, India, Regional Office for South-East Asia New Delhi 21-25 June 2004, WHO Project: ICP TUB 001
3. Richard, D.H., Mycek, J.M., Harvey, R.A. and Champe P.C. 2006. Lippincott's Illustrated reviews: Pharmacology. 3rd Edition. Baltimore. pp 395-440
4. Pablos, M.A., Raviglione, M.C., Laszlo, A., Binkin, N., Rieder, H.L., Bustreo, F., Cohn, D.L., Lambregts-van, Weezenbeek, C.S.B., Kim, S.J., Chaulet, P. and Nunn, P. 1998. Global surveillance for anti-tuberculosis drug resistance, 1994-1997. N. Engl. J. Med. 338:1641-1649.
5. Maria I.M.F., Caldas, P.C.S., Said, A., Martins, F. and Brito, C.R. 2004. Antimicrobial susceptibility determined by the E test, Lowenstein Jensen proportion, and DNA sequencing methods among Mycobacterium tuberculosis isolates - discrepancies, preliminary results. Mem. Inst. Oswaldo Cruz, Rio De Janeiro 99:107-110
6. Stephen, H.G. 2002. Evolution of drug resistance in M. tuberculosis. Clinical and molecular perspective of antimicrobial agents and chemotherapy. DOI: 10.1128/AAC.46.2.267-274. pp. 267-274
7. Pontali, E. and Narain, J.P. 2002. Tuberculosis and Special Situations: An Annotated Bibliography. WHO Project: ICP TUB 001.SEA-TB-244. World Health Organization Regional Office for South-East Asia, New Delhi.
8. Mokrousov, I.O., Narvskaya, T., Otten, A., Vyazovaya, E., Limeschenko, L., Steklova, L. and Vyshnevskyi, B. 2002. Phylogenetic reconstruction within Mycobacterium tuberculosis Beijing genotype in northwestern Russia. Res. Microbiol.153:629-637.
9. Bifani, P.J.B., Mathema, N.E., Kurepina, and Kreiswirth, B.N. 2002. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol. 10:45-52.
10. Van, R.A., Warren, R.M., Beyers, N., Gie, R.P., Classen, C.N., Richardson, M., Sampson, S.L., Victor, T.C. and van Helden, P.D. 1999. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling "strain W" among noninstitutionalized, human immunodeficiency virus-seronegative patients. J. Infect. Dis. 180:1608-1615
11. Jasmer, R.M., Roemer, M., Hamilton, J., Bunter, J., Braden, C.R., Shinnick, T.M. and Desmond, E.P. 2002. A prospective, multicenter study of laboratory cross-contamination of Mycobacterium tuberculosis cultures. Emerg. Infect. Dis. 8:1260-1263.
12. th Ed. Eds. Mandell, G.L., Bennett, J.E. and Dolin, R., pp. 348-361. Churchill Livingstone, Inc., Philadelphia
13. Richard, D.H., Mycek, J.M., Harvey, R.A. and Champe P.C. 2006. Lippincott's Illustrated reviews: Pharmacology. 3rd Edition. Baltimore. pp 395-440
14. Joel, G.H., Limbird, L.E. and Gillman, G.A. 2001. Goodman and Gilman's: The pharmacological basis of therapeutics. 10th Edition 2001. McGraw-Hill. New York, USA.
15. Bertram, G.K. 2004. Basic and Clinical Pharmacology. 9th Edition (2004). McGraw Hill, New York, pp. 782-790.
16. Nazir, T., Hameed A., Akhtar M.A., Shabbir E., Qureshi J.A., Malik A. and Qaisar M.N. 2008. Pyrazinamide resistance of Mycobacterium tuberculosis strains, isolated from human patients. Pharmacologyonline 3:948-957
17. Miah, M.R., Ali, M.S., Saleh, A.A. and Sattar, H. 2000. Primary drug resistance pattern of M. tuberculosis in Dhaka, Bangladesh. Bangladesh Med. Res. Counc. Bull. 26:33-40.
18. Bitar, D., Infuso, A., Barboza, P., Euro,T.B., Heersma, H., Kremer, K., Soolingen, D.V.M., Dufaux, F., Havelkova, M., Prikazsky, V., Lillebaeck, T., Gutierrez, C., Kubica, T., Niemann, S., Brum, L., Iglesias, M. J., Martin, C., Samper, S. and Ghebremichael. S. 2001. Clustering of multidrug resistant tuberculosis cases from nine European countries, 1998-2001. Institut de Veille Sanitaire, Saint-Maurice Fran
19. Uplekar, M.W., Rangan, S., Weiss, M.G., Ogden, J. and Borgdorff, M.W. 2001. Attention to gender issues in tuberculosis control. Int. J. Tub. Lung Dis, 5:220-224.
20. Haq, M.A., Khan, S.R., Saeed, S.U., Iqbal, S., Shabbir, R. and Magsi, J. 2002. Sensitivity Pattern of M. tuberculosis at Lahore (Pakistan). Ann KEMC 8:190-93.
21. WHO/ IUATLD. 2000. Anti-tuberculosis drug resistance in the world report No. 4, prevalence and trend. Published in 2008 and available online, Geneva, World Heath Organization, USA.
22. Herendra, T. and Shah, J.R. 1998. Multidrug resistance pulmonary tuberculosis. Ind. J. Tub. 45:131.
23. Rizwan, I., Shabbir, I., Nazir, M. and Hasan, M. 2003. TB drug resistance an alarming challenge - answer DOTS. Pakistan J. Med. Res. 42:2003
24. Centre of Disease Control and Prevention (CDCP). 2004. Drug susceptibility testing of M. tuberculosis& non-tuberculosis Mycobacteria, performance evaluation program. Division of Laboratory Services, USA.
25. Karin, C.W., Bateman, E., Blumberg, L., Cameron, N., Calver, A., Churchyard, G., Fourie, B., Brown, B.G., Matji, R. and Wilcox, P. 1997. The management of Multidrug resistant tuberculosis in South Africa. Guidelines for the management of multidrug-resistant tuberculosis patients in South Africa. National Tuberculosis Research Programme, Medical Research Council, Pretoria.
26. Grimm, H. 1978. In vitro investigation of rifampicn. Correlation between minimal inhibitory concentration and minimal inhibitory zone. Arzneimittelforschung 28:735-8
27. Canada Communicable Disease Report (CCDR). 2004. Tuberculosis Drugs Resistance; Summary Report (2003). Canadian Health Agency, Canada. Vol. 30: 10-13
28. Venkatesan, D. 1989. Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin. Pharmacokinet 16:365-86.
29. Juan, M.B.D. 2006. Long term health care treatment of tuberculosis. Department of Respiratory Medicine. Hospital Universitat Autònoma de Barcelona.
30. Praharaj, A.K., Kalghatgi, A.T., Varghese, S.J. and Nagendra, A. 2004. Incidence and drug susceptibility pattern of M. tuberculosis in HIV infected patients. MJAFI 60:134-136